229 related articles for article (PubMed ID: 23721786)
21. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Li Y; Liu W; Oo TF; Wang L; Tang Y; Jackson-Lewis V; Zhou C; Geghman K; Bogdanov M; Przedborski S; Beal MF; Burke RE; Li C
Nat Neurosci; 2009 Jul; 12(7):826-8. PubMed ID: 19503083
[TBL] [Abstract][Full Text] [Related]
22. LRRK2 G2019S Induces Anxiety/Depression-like Behavior before the Onset of Motor Dysfunction with 5-HT
Lim J; Bang Y; Choi JH; Han A; Kwon MS; Liu KH; Choi HJ
J Neurosci; 2018 Feb; 38(7):1611-1621. PubMed ID: 29305532
[TBL] [Abstract][Full Text] [Related]
23. (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model.
Weng YH; Chen CY; Lin KJ; Chen YL; Yeh TH; Hsiao IT; Chen IJ; Lu CS; Wang HL
Exp Neurol; 2016 Jan; 275 Pt 1():104-15. PubMed ID: 26363496
[TBL] [Abstract][Full Text] [Related]
24. Mouse models for LRRK2 Parkinson's disease.
Xu Q; Shenoy S; Li C
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
[TBL] [Abstract][Full Text] [Related]
25. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
[TBL] [Abstract][Full Text] [Related]
26. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Sharma N; Nehru B
Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
[TBL] [Abstract][Full Text] [Related]
27. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
Xiao Q; Yang S; Le W
J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
[TBL] [Abstract][Full Text] [Related]
28. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
[TBL] [Abstract][Full Text] [Related]
29. Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival.
Kang J; Huang G; Ma L; Tong Y; Shahapal A; Chen P; Shen J
Elife; 2024 Jun; 12():. PubMed ID: 38856715
[TBL] [Abstract][Full Text] [Related]
30. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
[TBL] [Abstract][Full Text] [Related]
31. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
32. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
Estanga A; Rodriguez-Oroz MC; Ruiz-Martinez J; Barandiaran M; Gorostidi A; Bergareche A; Mondragon E; Lopez de Munain A; Marti-Masso JF
Parkinsonism Relat Disord; 2014 Oct; 20(10):1097-100. PubMed ID: 25127457
[TBL] [Abstract][Full Text] [Related]
33. Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.
Huang G; Bloodgood DW; Kang J; Shahapal A; Chen P; Kaganovsky K; Kim JI; Ding JB; Shen J
J Neurosci; 2022 Jun; 42(23):4755-4765. PubMed ID: 35534227
[TBL] [Abstract][Full Text] [Related]
34. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
[TBL] [Abstract][Full Text] [Related]
35. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
36. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
37. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
Tai W; Ye X; Bao X; Zhao B; Wang X; Zhang D
Neuropharmacology; 2013 Dec; 75():201-12. PubMed ID: 23916477
[TBL] [Abstract][Full Text] [Related]
39. Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice.
Feng YK; Wu QL; Peng YW; Liang FY; You HJ; Feng YW; Li G; Li XJ; Liu SH; Li YC; Zhang Y; Pei Z
J Neuroinflammation; 2020 Nov; 17(1):347. PubMed ID: 33213462
[TBL] [Abstract][Full Text] [Related]
40. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
